Automated link 48

Manufactured by Agilent Technologies

The Automated Link 48 is a lab equipment product from Agilent Technologies. It is designed for automated sample preparation and analysis. The core function of the Automated Link 48 is to provide a streamlined and efficient workflow for processing multiple samples in a laboratory setting.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Automated Link 48 platform Dako Automated Link 48 platform Link 48

2 protocols using automated link 48

PD-L1 Immunohistochemistry in Medulloblastoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry of PD-L1 in 29 medulloblastoma samples was performed using the Dako EnVision FLEX + HRP-polymer kit (22C3 clone). The slides were submitted to deparaffinization and rehydration, followed by antigen retrieval (Dako EnVision FLEX Target Retrieval pH6). Staining was performed in the Dako Automated Link 48, and the PD-L1 antibody was prepared following the manufacturer’s instructions and previous studies, using the lung cancer cell line NCI-H226 as a positive control (35 (link)). Lastly, the slides were counterstained with hematoxylin. The intensity staining was determined as follows: 1+ (weak), 2+ (moderate) or 3+ (strong) (36 (link)).

Marques R.F., Moreno D.A., da Silva L., Leal L.F., de Paula F.E., Santana I., Teixeira G., Saggioro F., Neder L., Junior C.A., Mançano B, & Reis R.M. (2023). Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets. Frontiers in Immunology, 14, 1062856.

+ Open protocol

+ Expand

PD-L1 Expression Analysis Using 22C3 IHC

Check if the same lab product or an alternative is used in the 5 most similar protocols

PD-L1 IHC testing with proper controls using the PD-L1 clone 22C3 pharmDx kit on the Dako Automated Link 48 platform (Dako, Carpenteria, CA) was performed at Integrated Oncology/LabCorp (New York, NY). The PD-L1 TPS was calculated as the percentage of at least 100 viable tumor cells with complete or partial membrane staining, with tumor cells assessed morphologically by comparison to a serially cut Hematoxylin and Eosin stained slide. Tumor PD-L1 expression was divided into three clinically relevant TPS groups: <1% (no expression), 1–49% (low expression), and ≥50% (high expression). The TPS interpretations that were provided by the commercial vendor’s pathologists were the values used in this study, with verification by slide review by a board certified cytopathologist and surgical pathologist with subspecialty expertise in pulmonary pathology (PVL).

Torous V.F., Rangachari D., Gallant B.P., Shea M., Costa D.B, & VanderLaan P.A. (2018). PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. Journal of the American Society of Cytopathology, 7(3), 133-141.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!